Follow-Up Consultation Report

Patient Information

Name: Emily Johnson **DOB:** April 25, 1965

Email: emily.johnson@example.com

Allergies: Penicillin

Medical Record Number: 789101

Appointment Details

Date: May 18, 2024 **Time:** 11:00 AM

Doctor: Dr. Michael Adams, MD

Chief Complaint

Follow-up for breast cancer treatment.

History of Present Illness

Emily Johnson is a 59-year-old female diagnosed with HER2-positive breast cancer in June 2023. She has completed 4 cycles of docetaxel and trastuzumab and is currently on maintenance trastuzumab

Past Medical History

- Hypothyroidism
- Osteoporosis

Medications

• Trastuzumab: 6 mg/kg IV every 3 weeks

Levothyroxine: 75 mcg PO QDAlendronate: 70 mg PO weekly

Review of Systems

Constitutional: Weight loss, fatigue
Respiratory: No dyspnea, no cough

Cardiovascular: No chest pain or palpitations
 Gastrointestinal: No nausea or vomiting

Physical Examination

• General: Well-nourished, no acute distress

• Vital Signs: BP 125/80, HR 72, RR 16, Temp 98.4°F

Breast: No masses, no tendernessChest/Lungs: Clear to auscultation

• Cardiovascular: Regular rhythm, no murmurs

• **Abdomen:** Non-tender, no organomegaly

Assessment

- HER2-positive breast cancer, stable
- Hypothyroidism, controlled
- Osteoporosis

Plan

- 1. Continue trastuzumab maintenance therapy.
- 2. Schedule a mammogram in 6 months.
- 3. Routine blood tests including TSH and calcium.
- 4. Follow-up in 3 months to review labs and clinical status.

Signed:

Dr. Michael Adams, MD Oncologist, Vita Clinic michael.adams@vitaclinic.com